Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre studyWalter Reinisch, Fabio Cataldi, Margot O’Toole et al.|Gut|2015Cited by 157
Mo1207 Discrepancy Between Fecal Biomarkers and Their Intestinal Gene Expression in Ulcerative Colitis: Results From an Anti-IL-13 Antibody StudyWalter Reinisch, Fabio Cataldi, Julián Panés et al.|Gastroenterology|2014Cited by 1
IMA-638 in Active Ulcerative Colitis: Efficacy and Safety from a Phase IIa Multicenter StudySunil Khurana, Walter Reinisch, Julián Panés et al.|The American Journal of Gastroenterology|2013Cited by 0
IMA-638 in Active Ulcerative Colitis from a Phase IIa Multicenter Study: Correlation between Fecal Calprotectin Levels and Clinical ActivitySunil Khurana, Walter Reinisch, Julián Panés et al.|The American Journal of Gastroenterology|2013Cited by 0